Literature DB >> 7438687

Concentrations and kinetics of carbamazepine in whole saliva, parotid saliva, serum ultrafiltrate, and serum.

J W Paxton, R A Donald.   

Abstract

Six healthy subjects received a 400-mg oral dose of carbamazepine (CBZ). CBZ concentrations were determined by enzyme immunoassay in whole saliva, serum, and serum ultrafiltrate over 82 hr. After 30 hr the log concentration-time plots declined linearly with similar elimination half-lifes in all three fluids. Although the mean ultrafiltrate curve was lower than the mean salivary curve, the area under the curve, volume of distribution, and total body clearance calculated from whole saliva and ultrafiltrate data were not different. The mean CBZ concentration ratios of whole saliva/total serum and ultrafiltrate/total serum of the individual subjects ranged from 19.6% to 34.7% and from 19.0% to 28.8%. Linear correlations were found between salivary CBZ concentrations and serum (r = 0.872, p < 0.001) and ultrafiltrate concentrations (r = 0.916, p < 0.001). Whole salivary and uncontaminated parotid salivary CBZ concentrations were not different and were independent of volume of fluid produced, pH of saliva, and degree of stimulation. These results indicate that whole saliva may be a suitable medium for monitoring free concentrations of CBZ and may provide a noninvasive alternative to blood.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438687     DOI: 10.1038/clpt.1980.223

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Factors affecting the determination of unbound carbamazepine concentrations in plasma.

Authors:  J J Lohman; F W Merkus; G M Costongs; E P Hegtermans; P M Hooymans
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200

Review 3.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

4.  The effects of age on carbamazepine pharmacokinetics and adverse effects.

Authors:  N Hockings; A Pall; J Moody; A V Davidson; D L Davidson
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

5.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

6.  Ultrafiltration vs equilibrium dialysis for determination of free fraction.

Authors:  W F Bowers; S Fulton; J Thompson
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Pitfalls in the determination of unbound carbamazepine concentrations in plasma.

Authors:  J J Lohman; F W Merkus; G M Costongs; E P Hegtermans; P M Hooymans
Journal:  Pharm Weekbl Sci       Date:  1984-04-27

Review 8.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 9.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

10.  Investigating Oral Absorption of Carbamazepine in Pediatric Populations.

Authors:  Philip Kohlmann; Cordula Stillhart; Martin Kuentz; Neil Parrott
Journal:  AAPS J       Date:  2017-10-02       Impact factor: 4.009

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.